Phase II trial of carboplatin in patients with metastatic malignant melanoma

Alex Y Chang, M. Hunt, D. R. Parkinson, H. Hochster, T. J. Smith

Research output: Contribution to journalArticle

Abstract

Thirty patients with pathologically proven, measurable metastatic melanoma without prior chemotherapy were treated with carboplatin 400 mg/m2 by intravenous infusion for 30 minutes every 4 weeks. Twenty-seven patients were evaluable for response and toxicity. Two complete responses and one partial response (3 of 27 = 11%, 90% confidence intervals: 3-26%) were documented. The median survival was 4.7 months. The most common toxicity was myelosuppression. One drug-related death was observed due to renal failure. Prior radiotherapy and liver metastasis were the poor prognostic indicators identified in our study. Carboplatin in the dose and schedule reported in our trial has only modest antitumor activity in patients with advanced malignant melanoma.

Original languageEnglish (US)
Pages (from-to)152-155
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number2
StatePublished - 1993
Externally publishedYes

Fingerprint

Carboplatin
Melanoma
Intravenous Infusions
Renal Insufficiency
Appointments and Schedules
Radiotherapy
Confidence Intervals
Neoplasm Metastasis
Drug Therapy
Survival
Liver
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of carboplatin in patients with metastatic malignant melanoma. / Chang, Alex Y; Hunt, M.; Parkinson, D. R.; Hochster, H.; Smith, T. J.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 16, No. 2, 1993, p. 152-155.

Research output: Contribution to journalArticle

Chang, Alex Y ; Hunt, M. ; Parkinson, D. R. ; Hochster, H. ; Smith, T. J. / Phase II trial of carboplatin in patients with metastatic malignant melanoma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1993 ; Vol. 16, No. 2. pp. 152-155.
@article{870a43320e1e47b18e82271f5320ecc9,
title = "Phase II trial of carboplatin in patients with metastatic malignant melanoma",
abstract = "Thirty patients with pathologically proven, measurable metastatic melanoma without prior chemotherapy were treated with carboplatin 400 mg/m2 by intravenous infusion for 30 minutes every 4 weeks. Twenty-seven patients were evaluable for response and toxicity. Two complete responses and one partial response (3 of 27 = 11{\%}, 90{\%} confidence intervals: 3-26{\%}) were documented. The median survival was 4.7 months. The most common toxicity was myelosuppression. One drug-related death was observed due to renal failure. Prior radiotherapy and liver metastasis were the poor prognostic indicators identified in our study. Carboplatin in the dose and schedule reported in our trial has only modest antitumor activity in patients with advanced malignant melanoma.",
author = "Chang, {Alex Y} and M. Hunt and Parkinson, {D. R.} and H. Hochster and Smith, {T. J.}",
year = "1993",
language = "English (US)",
volume = "16",
pages = "152--155",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Phase II trial of carboplatin in patients with metastatic malignant melanoma

AU - Chang, Alex Y

AU - Hunt, M.

AU - Parkinson, D. R.

AU - Hochster, H.

AU - Smith, T. J.

PY - 1993

Y1 - 1993

N2 - Thirty patients with pathologically proven, measurable metastatic melanoma without prior chemotherapy were treated with carboplatin 400 mg/m2 by intravenous infusion for 30 minutes every 4 weeks. Twenty-seven patients were evaluable for response and toxicity. Two complete responses and one partial response (3 of 27 = 11%, 90% confidence intervals: 3-26%) were documented. The median survival was 4.7 months. The most common toxicity was myelosuppression. One drug-related death was observed due to renal failure. Prior radiotherapy and liver metastasis were the poor prognostic indicators identified in our study. Carboplatin in the dose and schedule reported in our trial has only modest antitumor activity in patients with advanced malignant melanoma.

AB - Thirty patients with pathologically proven, measurable metastatic melanoma without prior chemotherapy were treated with carboplatin 400 mg/m2 by intravenous infusion for 30 minutes every 4 weeks. Twenty-seven patients were evaluable for response and toxicity. Two complete responses and one partial response (3 of 27 = 11%, 90% confidence intervals: 3-26%) were documented. The median survival was 4.7 months. The most common toxicity was myelosuppression. One drug-related death was observed due to renal failure. Prior radiotherapy and liver metastasis were the poor prognostic indicators identified in our study. Carboplatin in the dose and schedule reported in our trial has only modest antitumor activity in patients with advanced malignant melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0027456440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027456440&partnerID=8YFLogxK

M3 - Article

C2 - 8452109

AN - SCOPUS:0027456440

VL - 16

SP - 152

EP - 155

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -